Encorafenib

468 interactions 398 cited references
Also sold as: Braftovi Braftovi®
About Encorafenib

Encorafenib is used along with binimetinib (Mektovi) to treat certain types of melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be removed by surgery. It is also used with cetuximab (Erbitux) to treat a certain type of colon cancer in adults that has spread to other parts of the bod… Read the full Encorafenib drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Atazanavir Posaconazole Ranolazine Piperaquine Doravirine Pimozide
36 Contraindicated 392 Major 40 Moderate
All (468) Contraindicated (36) Major (392) Moderate (40)

Major

Encorafenib Octreotide Bynfezia Increased risk of QT interval prolongation Details Encorafenib Ofloxacin Floxin® Increased risk of QT interval prolongation Details Encorafenib Olanzapine Increased risk of QT interval prolongation Details Encorafenib Oliceridine Olinvyk Reduced oliceridine exposure and reduced efficacy of oliceridine Details Encorafenib Olodaterol Striverdi An increased risk of QT interval prolongation and an increased risk of ventricular arrhythmias Details Encorafenib Omaveloxolone Skyclarys Reduced omaveloxolone exposure, reduced efficacy of omaveloxolone, reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A... Details Encorafenib Ondansetron Increased risk of QT interval prolongation Details Encorafenib Orforglipron Foundayo Reduced orforglipron exposure and reduced efficacy of orforglipron Details Encorafenib Osilodrostat Isturisa Increased risk of QT interval prolongation Details Encorafenib Osimertinib Tagrisso Increased risk of QT interval prolongation Details Encorafenib Oxaliplatin Increased risk of QT interval prolongation Details Encorafenib Ozanimod Increased ozanimod exposure, an increased risk of ozanimod-related toxicities, additive effects on heart rate and an increased ris... Details Encorafenib Pacritinib Vonjo® An increased risk of QT interval prolongation Details Encorafenib Paliperidone Erzofri Increased risk of QT interval prolongation Details Encorafenib Paltusotine Palsonify Reduced paltusotine exposure and reduced efficacy of paltusotine Details Encorafenib Panobinostat Farydak Increased risk of QT interval prolongation Details Encorafenib Papaverine Pavacot® Increased risk of QT interval prolongation Details Encorafenib Paritaprevir Increased encorafenib exposure, an increased risk of encorafenib-related adverse events, altered (increased/reduced) paritaprevir... Details Encorafenib Paroxetine Paxil Increased risk of QT interval prolongation Details Encorafenib Pasireotide Signifor Increased risk of QT interval prolongation Details Encorafenib Pazopanib Votrient Increased risk of QT interval prolongation Details Encorafenib Pentamidine NebuPent Increased risk of QT interval prolongation Details Encorafenib Perphenazine Increased risk of QT interval prolongation Details Encorafenib Phenobarbital Fidoquel Reduced encorafenib exposure and reduced efficacy of encorafenib Details Encorafenib Phenytoin Dilantin Reduced encorafenib exposure and reduced efficacy of encorafenib Details Encorafenib Pimavanserin Nuplazid Increased risk of QT interval prolongation Details Encorafenib Pipamperone Increased risk of QT interval prolongation Details Encorafenib Pitolisant Wakix Reduced pitolisant exposure, an increased risk of QT interval prolongation and an increased risk of cardiac arrhythmias Details Encorafenib Ponesimod Ponvory An increased risk of QT interval prolongation Details Encorafenib Primidone Mysoline Reduced encorafenib exposure and reduced efficacy of encorafenib Details Encorafenib Probucol Increased risk of QT interval prolongation Details Encorafenib Procainamide Procan® Increased risk of QT interval prolongation Details Encorafenib Prochlorperazine Increased risk of QT interval prolongation Details Encorafenib Promethazine Phenadoz Increased risk of QT interval prolongation Details Encorafenib Propafenone Rythmol Increased risk of QT interval prolongation Details Encorafenib Protriptyline Increased risk of QT interval prolongation Details Encorafenib Quetiapine Seroquel Reduced CYP3A4 substrate exposure, reduced efficacy of CYP3A4 substrate and an increased risk of QT interval prolongation Details Encorafenib Quinidine Cardioquin® Increased risk of QT interval prolongation Details Encorafenib Quinine Increased risk of QT interval prolongation Details Encorafenib Quizartinib Vanflyta Reduced quizartinib exposure, reduced the efficacy of quizartinib and an increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.